Stryker Corp
SYK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$513.00 | Rkpt | Ztwvnlyxy |
Stryker's New Product Cycle Should Support Above-Market Growth Into 2025
Business Strategy and Outlook
Stryker remains a top-tier competitor in a number of attractive medical markets, including orthopedic implants, surgical instruments, endoscopy, and neurovascular devices. It enjoys a long record of innovation in its key markets, and we anticipate the pattern will continue, allowing the wide-moat company to earn attractive economic profits.